Glioma immunology and immunotherapy

Ian F Parney, Chunhai Hao, Kenneth C. Petruk

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

OBJECTIVE: Despite advances in conventional therapy, the prognosis for most glioma patients remains dismal. This has prompted an intensive search for effective treatment alternatives. Immunotherapy, one such alternative, has long been recognized as a potentially potent cancer treatment but has been limited by an inadequate understanding of the immune system. Now, increased insight into immunology is suggesting more rational approaches to immunotherapy. In this article, we explore key aspects of modern immunology and discuss their implications for glioma therapy. METHODS: A thorough literature review of glioma immunology and immunotherapy was undertaken to inquire into the basic immunology, central nervous system immunology, glioma immunobiology, standard glioma immunotherapy, and recent immunotherapeutic advances in glioma treatment. RESULTS: Although gliomas express tumor- associated antigens and appear potentially sensitive to immune responses, many factors work together to inhibit antiglioma immunity. Not surprisingly, most clinical attempts at glioma immunotherapy have met with little success to date. However, novel immunostimulatory strategies, such as immunogene therapy, directed cytokine delivery, and dendritic cell manipulation, have recently yielded dramatic preclinical results in glioma models. This suggests that glioma-derived immunosuppression can be overcome. CONCLUSION: Modern molecular biology and immunology techniques have yielded a wealth of new data about glioma immunobiology. Armed with this information, many investigators have proposed novel means to stimulate antiglioma immune responses. Although definitive clinical results remain to be seen, the current renaissance in glioma immunology and immunotherapy shows great promise for the future.

Original languageEnglish (US)
Pages (from-to)778-792
Number of pages15
JournalNeurosurgery
Volume46
Issue number4
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Allergy and Immunology
Glioma
Immunotherapy
Therapeutics
Neoplasm Antigens
Immunosuppression
Dendritic Cells
Molecular Biology
Immune System
Immunity
Central Nervous System
Research Personnel
Cytokines

Keywords

  • Cytokine
  • Gene therapy
  • Glioma
  • Immunology
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Parney, I. F., Hao, C., & Petruk, K. C. (2000). Glioma immunology and immunotherapy. Neurosurgery, 46(4), 778-792.

Glioma immunology and immunotherapy. / Parney, Ian F; Hao, Chunhai; Petruk, Kenneth C.

In: Neurosurgery, Vol. 46, No. 4, 04.2000, p. 778-792.

Research output: Contribution to journalArticle

Parney, IF, Hao, C & Petruk, KC 2000, 'Glioma immunology and immunotherapy', Neurosurgery, vol. 46, no. 4, pp. 778-792.
Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery. 2000 Apr;46(4):778-792.
Parney, Ian F ; Hao, Chunhai ; Petruk, Kenneth C. / Glioma immunology and immunotherapy. In: Neurosurgery. 2000 ; Vol. 46, No. 4. pp. 778-792.
@article{28e2fedfc90c4e96b9e0c6d123ec1ced,
title = "Glioma immunology and immunotherapy",
abstract = "OBJECTIVE: Despite advances in conventional therapy, the prognosis for most glioma patients remains dismal. This has prompted an intensive search for effective treatment alternatives. Immunotherapy, one such alternative, has long been recognized as a potentially potent cancer treatment but has been limited by an inadequate understanding of the immune system. Now, increased insight into immunology is suggesting more rational approaches to immunotherapy. In this article, we explore key aspects of modern immunology and discuss their implications for glioma therapy. METHODS: A thorough literature review of glioma immunology and immunotherapy was undertaken to inquire into the basic immunology, central nervous system immunology, glioma immunobiology, standard glioma immunotherapy, and recent immunotherapeutic advances in glioma treatment. RESULTS: Although gliomas express tumor- associated antigens and appear potentially sensitive to immune responses, many factors work together to inhibit antiglioma immunity. Not surprisingly, most clinical attempts at glioma immunotherapy have met with little success to date. However, novel immunostimulatory strategies, such as immunogene therapy, directed cytokine delivery, and dendritic cell manipulation, have recently yielded dramatic preclinical results in glioma models. This suggests that glioma-derived immunosuppression can be overcome. CONCLUSION: Modern molecular biology and immunology techniques have yielded a wealth of new data about glioma immunobiology. Armed with this information, many investigators have proposed novel means to stimulate antiglioma immune responses. Although definitive clinical results remain to be seen, the current renaissance in glioma immunology and immunotherapy shows great promise for the future.",
keywords = "Cytokine, Gene therapy, Glioma, Immunology, Immunotherapy",
author = "Parney, {Ian F} and Chunhai Hao and Petruk, {Kenneth C.}",
year = "2000",
month = "4",
language = "English (US)",
volume = "46",
pages = "778--792",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Glioma immunology and immunotherapy

AU - Parney, Ian F

AU - Hao, Chunhai

AU - Petruk, Kenneth C.

PY - 2000/4

Y1 - 2000/4

N2 - OBJECTIVE: Despite advances in conventional therapy, the prognosis for most glioma patients remains dismal. This has prompted an intensive search for effective treatment alternatives. Immunotherapy, one such alternative, has long been recognized as a potentially potent cancer treatment but has been limited by an inadequate understanding of the immune system. Now, increased insight into immunology is suggesting more rational approaches to immunotherapy. In this article, we explore key aspects of modern immunology and discuss their implications for glioma therapy. METHODS: A thorough literature review of glioma immunology and immunotherapy was undertaken to inquire into the basic immunology, central nervous system immunology, glioma immunobiology, standard glioma immunotherapy, and recent immunotherapeutic advances in glioma treatment. RESULTS: Although gliomas express tumor- associated antigens and appear potentially sensitive to immune responses, many factors work together to inhibit antiglioma immunity. Not surprisingly, most clinical attempts at glioma immunotherapy have met with little success to date. However, novel immunostimulatory strategies, such as immunogene therapy, directed cytokine delivery, and dendritic cell manipulation, have recently yielded dramatic preclinical results in glioma models. This suggests that glioma-derived immunosuppression can be overcome. CONCLUSION: Modern molecular biology and immunology techniques have yielded a wealth of new data about glioma immunobiology. Armed with this information, many investigators have proposed novel means to stimulate antiglioma immune responses. Although definitive clinical results remain to be seen, the current renaissance in glioma immunology and immunotherapy shows great promise for the future.

AB - OBJECTIVE: Despite advances in conventional therapy, the prognosis for most glioma patients remains dismal. This has prompted an intensive search for effective treatment alternatives. Immunotherapy, one such alternative, has long been recognized as a potentially potent cancer treatment but has been limited by an inadequate understanding of the immune system. Now, increased insight into immunology is suggesting more rational approaches to immunotherapy. In this article, we explore key aspects of modern immunology and discuss their implications for glioma therapy. METHODS: A thorough literature review of glioma immunology and immunotherapy was undertaken to inquire into the basic immunology, central nervous system immunology, glioma immunobiology, standard glioma immunotherapy, and recent immunotherapeutic advances in glioma treatment. RESULTS: Although gliomas express tumor- associated antigens and appear potentially sensitive to immune responses, many factors work together to inhibit antiglioma immunity. Not surprisingly, most clinical attempts at glioma immunotherapy have met with little success to date. However, novel immunostimulatory strategies, such as immunogene therapy, directed cytokine delivery, and dendritic cell manipulation, have recently yielded dramatic preclinical results in glioma models. This suggests that glioma-derived immunosuppression can be overcome. CONCLUSION: Modern molecular biology and immunology techniques have yielded a wealth of new data about glioma immunobiology. Armed with this information, many investigators have proposed novel means to stimulate antiglioma immune responses. Although definitive clinical results remain to be seen, the current renaissance in glioma immunology and immunotherapy shows great promise for the future.

KW - Cytokine

KW - Gene therapy

KW - Glioma

KW - Immunology

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034118217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034118217&partnerID=8YFLogxK

M3 - Article

C2 - 10764250

AN - SCOPUS:0034118217

VL - 46

SP - 778

EP - 792

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -